• ___
  • Svenska
  • Career
  • Contact
  • About IRLAB
    • About IRLAB
  • Therapeutic focus
    • Therapeutic focus
    • Parkinson’s disease
      • Patient portrait
    • PD-LIDs
    • PD-Falls
  • Project portfolio
    • Project portfolio
    • Mesdopetam (IRL790)
    • Pirepemat (IRL752)
    • IRL942 & 1009
    • Discovery phase
  • Research platform
    • ISP platform
    • Scientific publications
  • Newsroom
    • Newsroom
    • Presentations & events
    • Press releases
    • Event calendar
    • Image library
  • Investors
    • Investors
    • Financial reports
    • The share
      • Owners
      • Share capital development
      • PDMR transactions
      • Analysts
    • Financial calendar
    • Listing Nasdaq Stockholm Main Market 2020
    • Rights issue Feb 2020
    • Initial public offering 2017
  • Corporate Governance
    • Corporate Governance
    • General Meetings
      • Annual General Meeting 2021
      • Previous general meetings
    • Corporate governance reports
    • Board of directors
    • Nomination committee
      • Nomination Committee for AGM 2021
      • Previous nomination committees
    • Management
    • Auditor
    • Remuneration
    • Certified advisor
    • Internal control
    • Diversity
    • Articles of association
Hem>Investors>The share

The share

Share this:
  • Facebook
  • Twitter
  • Linkedin
  • Investors
    • Investors
    • Financial reports
    • The share
      • Owners
      • Share capital development
      • PDMR transactions
      • Analysts
    • Financial calendar
    • Listing Nasdaq Stockholm Main Market 2020
    • Rights issue Feb 2020
    • Initial public offering 2017

IRLAB Therapeutics AB (publ)

Arvid Wallgrens Backe 20

413 46 Göteborg

+46 31 757 38 00

Copyright © 2021 IRLAB

  • Integrity policy
image/svg+xml